en POLSKI
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees

Journal integrated with

integrated with publons
3/2021
vol. 27
 
Share:
Send email
Share:
abstract:
Review paper

Mucopolysaccharidosis III: Molecular basis and treatment

Lidvana Spahiu
1
,
Emir Behluli
1
,
Borut Peterlin
2
,
Hilada Nefic
3
,
Rifat Hadziselimovic
3
,
Thomas Liehr
4
,
Gazmend Temaj
5

  1. Pediatric Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo
  2. Department of Genetics and Genomics, University Clinical Center Ljubljana, Slovenia
  3. Faculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina, Bosnia and Herzegovina
  4. Institut für Humangenetik, Universitätsklinikum Jena, Friedrich Schiller Universität, Jena Germany, Germany
  5. Human Genetics, College UBT, Faculty of Pharmacy Prishtina, Kosovo
Pediatr Endocrinol Diabetes Metab 2021; 27 (3): 199–208
DOI: https://doi.org/10.5114/pedm.2021.109270
Online publish date: 2021/09/30
View full text Get citation
 
PlumX metrics:
Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options.
keywords:

mucopolysaccharidosis III (MPS III), lysosomal storage diseases (LSDs), glycosaminoglycan, therapy for mucopolysccharidosis, clinical diagnosis

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.